Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Herbst on Immunotherapy Agents in Lung Cancer

February 13th 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the using immunotherapy agents to treat patients with lung cancer.

Hopes Revived for Targeting the "Undruggable" RAS Family

February 11th 2014

The members of the RAS oncogene family are central cogs in many different cell-signaling pathways, coordinate a variety of important cellular processes, and are highly mutated in a number of different cancers, including several with extremely poor prognosis.

Dr. Shaw on LDK378 and Alectinib for ALK+ NSCLC

February 10th 2014

Alice T. Shaw, MD, PhD, discusses the two most advanced next-generation ALK-inhibitors for the treatment of non-small cell lung cancer (NSCLC): LDK378 and alectinib (AF802).

Final Thoughts on Improving Outcomes in NSCLC

February 7th 2014

Skeletal-Related Event Management in Lung Cancer

February 7th 2014

Next-Generation Sequencing in Lung Cancer

February 7th 2014

Determining When to Administer Maintenance Therapy in NSCLC

February 7th 2014

Maintenance Therapy in Non-Small Cell Lung Cancer

February 7th 2014

Optimizing Maintenance Therapy in NSCLC

February 7th 2014

Adjuvant EGFR Inhibition in Patients With NSCLC

February 7th 2014

Next-Generation Targeted Therapies in NSCLC

February 7th 2014

Development of ALK Inhibitors in Advanced NSCLC

February 7th 2014

Second-Generation ALK Inhibitors in NSCLC

February 7th 2014

Current Status of Immunotherapy in NSCLC

February 7th 2014

Immune Checkpoint Inhibitor Combinations in NSCLC

February 7th 2014

Checkpoint Inhibitor Related Pseudoprogression in NSCLC

February 7th 2014

Introduction: Checkpoint Inhibition in NSCLC

February 7th 2014

Anti-PD-1 Antibody MK-3475 Advances Into Multiple Tumor Types

February 7th 2014

Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of its investigational anti-PD-1 immunotherapy MK-3475 across multiple tumor types

Dr. Herbst on the Benefit of Targeting PD-1/PD-L1

February 4th 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the unique benefit of targeting the PD-1/PD-L1 pathway in lung cancer.

Clinical Trial Changes Needed to Improve Outcomes in Stage III NSCLC

February 4th 2014

Treatment of stage III non-small cell lung cancer (NSCLC) with chemotherapy, radiation, and surgery has hit a plateau, and the key to improved outcomes will hinge on the testing of targeted therapies in clinical trials with more novel designs and better patient selection, according to a leading researcher.